Navigation Links
Skinvisible Appoints Dr. George Korkos to Its Advisory Board
Date:10/26/2007

technology does exactly that. I also like the fact that Skinvisible is dedicated to R&D and protecting their intellectual property at every turn; that's key in this industry."

Dr. Korkos received his degree from the Medical College of Wisconsin and did his plastic surgery residency at St. Louis University. He is currently the President of Plastic Surgery Associates in Milwaukee, Wisconsin and Blue Mound Surgery Center along with being an Associate Clinical Professor at the Medical College of Wisconsin. Recently Dr. Korkos was honored with the establishment of the first endowed chair at the Medical College of Wisconsin; The George J. Korkos Chair in Plastic Surgery. His business background is diverse. Along with sitting on Boards of emerging companies, Dr. Korkos has also served on the Board of a number of financial and investment institutions.

About Skinvisible Pharmaceuticals, Inc.

Skinvisible Pharmaceuticals, a wholly owned subsidiary of Skinvisible Inc., is a research-and-development company whose primary business objective is to license its proprietary formulations with Invisicare to pharmaceutical and cosmeceutical companies as well as assisting companies in revitalizing or enhancing their existing skin care products. Skinvisible receives a combination of research and development fees, upfront license fees, and ongoing royalties for the life of the patent. http://www.skinvisible.com

About Invisicare(R)

Invisicare is a patented polymer delivery system developed to hold active ingredients topically on the skin for extended periods of time. A key benefit is that Invisicare is non-occlusive on the skin, allowing normal skin respiration and perspiration. The Company has developed a portfolio of topical products using Invisicare for the dermatology and cosmeceutical industries. http://www.invisicare.com

Forward-Looking Stat
'/>"/>

SOURCE Skinvisible, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. George Bush pledges 200 million dollars for AIDS relief
2. Arsenic May Have Been Responsible For The Madness Of King George III Of England
3. Study Unveils New Insight To The Madness Of King George III
4. Investigation into the Poor Hospital Facility That Led To the Death of George Cook
5. Georgetown University Heads Alternative Tobacco Project
6. WHO lifts HongKong advisory
7. FDA Issues Public Health Advisory on Tysabri, a New Drug for MS
8. Doctors Said – ‘Stop Pressurising NHS Advisory Bod’
9. Mercks Pain Reliever Arcoxia Rejected by US Federal Advisory Panel
10. FDA Advisory Against Anti-depressants to Be Expanded to Cover Young Adults too
11. FDA Advisory Against Anti-depressants to Be Expanded to Cover Young Adults too
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 2The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 3The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 4The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 5Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 2Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 3Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 2Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 3Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin An Investigational Treatment for Type 2 Diabetes 4914 1Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin An Investigational Treatment for Type 2 Diabetes 4914 2Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin An Investigational Treatment for Type 2 Diabetes 4914 3IBM Scientists First to Image the Anatomy of a Molecule 4913 1IBM Scientists First to Image the Anatomy of a Molecule 4913 2IBM Scientists First to Image the Anatomy of a Molecule 4913 3IBM Scientists First to Image the Anatomy of a Molecule 4913 4IBM Scientists First to Image the Anatomy of a Molecule 4913 5Four Studies Published in The Lancet Show roflumilast 28Daxas 28R 29 29 a New Oral Approach to COPD Improves Lung Function and Reduces Exacerbation 4911 1Four Studies Published in The Lancet Show roflumilast 28Daxas 28R 29 29 a New Oral Approach to COPD Improves Lung Function and Reduces Exacerbation 4911 2Four Studies Published in The Lancet Show roflumilast 28Daxas 28R 29 29 a New Oral Approach to COPD Improves Lung Function and Reduces Exacerbation 4911 3Four Studies Published in The Lancet Show roflumilast 28Daxas 28R 29 29 a New Oral Approach to COPD Improves Lung Function and Reduces Exacerbation 4911 4Four Studies Published in The Lancet Show roflumilast 28Daxas 28R 29 29 a New Oral Approach to COPD Improves Lung Function and Reduces Exacerbation 4911 5Four Studies Published in The Lancet Show roflumilast 28Daxas 28R 29 29 a New Oral Approach to COPD Improves Lung Function and Reduces Exacerbation 4911 6Four Studies Published in The Lancet Show roflumilast 28Daxas 28R 29 29 a New Oral Approach to COPD Improves Lung Function and Reduces Exacerbation 4911 7Four Studies Published in The Lancet Show roflumilast 28Daxas 28R 29 29 a New Oral Approach to COPD Improves Lung Function and Reduces Exacerbation 4911 8Four Studies Published in The Lancet Show roflumilast 28Daxas 28R 29 29 a New Oral Approach to COPD Improves Lung Function and Reduces Exacerbation 4911 9